Whitebox Advisors Lifted Nxp Semiconductors N V (NXPI) Stake By $30.38 Million; Curis, Inc. (CRIS) Covered By 5 Bullish Analysts Last Week

December 13, 2017 - By Henry Gaston

Among 6 analysts covering Curis (NASDAQ:CRIS), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 83% are positive. Curis had 8 analyst reports since August 10, 2015 according to SRatingsIntel. Roth Capital maintained Curis, Inc. (NASDAQ:CRIS) rating on Monday, November 9. Roth Capital has “Buy” rating and $5 target. Guggenheim initiated the shares of CRIS in report on Monday, October 23 with “Buy” rating. The rating was downgraded by Zacks to “Sell” on Monday, September 21. On Tuesday, September 1 the stock rating was downgraded by Zacks to “Hold”. As per Monday, November 9, the company rating was maintained by TH Capital. The firm has “Outperform” rating by FBR Capital given on Tuesday, August 11. See Curis, Inc. (NASDAQ:CRIS) latest ratings:

06/12/2017 Broker: Cowen & Co Rating: Buy
23/10/2017 Broker: Guggenheim Rating: Buy New Target: $7.0 Initiate

Whitebox Advisors Llc increased Nxp Semiconductors N V (NXPI) stake by 135.94% reported in 2017Q2 SEC filing. Whitebox Advisors Llc acquired 278,685 shares as Nxp Semiconductors N V (NXPI)’s stock rose 5.22%. The Whitebox Advisors Llc holds 483,685 shares with $52.94M value, up from 205,000 last quarter. Nxp Semiconductors N V now has $39.30B valuation. The stock increased 0.24% or $0.28 during the last trading session, reaching $115.92. About 1.01 million shares traded. NXP Semiconductors N.V. (NASDAQ:NXPI) has risen 24.67% since December 13, 2016 and is uptrending. It has outperformed by 7.97% the S&P500.

The stock decreased 0.57% or $0.005 during the last trading session, reaching $0.814. About 957,515 shares traded. Curis, Inc. (NASDAQ:CRIS) has risen 2.47% since December 13, 2016 and is uptrending. It has underperformed by 14.23% the S&P500.

Investors sentiment decreased to 1.48 in 2017 Q2. Its down 0.04, from 1.52 in 2017Q1. It worsened, as 9 investors sold Curis, Inc. shares while 20 reduced holdings. 14 funds opened positions while 30 raised stakes. 72.75 million shares or 0.77% less from 73.32 million shares in 2017Q1 were reported. Bluecrest Capital Mngmt Ltd stated it has 0% in Curis, Inc. (NASDAQ:CRIS). Silvercrest Asset Grp stated it has 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS). Panagora Asset Mngmt accumulated 176,973 shares. Jacobs Levy Equity Inc reported 155,470 shares stake. Bridgeway has 0% invested in Curis, Inc. (NASDAQ:CRIS) for 84,160 shares. Strs Ohio has 0% invested in Curis, Inc. (NASDAQ:CRIS). 1,100 are owned by Captrust Fincl Advisors. Salem Inv Counselors Inc has 0% invested in Curis, Inc. (NASDAQ:CRIS) for 10,000 shares. Group One Trading Ltd Partnership holds 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS) for 9,427 shares. California Employees Retirement System holds 210,300 shares or 0% of its portfolio. Renaissance Limited Liability accumulated 261,700 shares or 0% of the stock. 8,583 are owned by Ameritas Investment Prtn Incorporated. Fincl Bank Of America De has invested 0% in Curis, Inc. (NASDAQ:CRIS). Citigroup Inc has invested 0% in Curis, Inc. (NASDAQ:CRIS). Prelude Limited Liability has 725 shares.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company has market cap of $133.48 million. The firm develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It currently has negative earnings. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis.

Whitebox Advisors Llc decreased C&J Energy Svcs Inc New stake by 572,447 shares to 2.53 million valued at $86.85 million in 2017Q2. It also reduced Ishares Tr (Put) stake by 100,000 shares and now owns 500,000 shares. Spdr S&P 500 Etf Tr (Put) was reduced too.

Among 28 analysts covering NXP Semiconductors NV (NASDAQ:NXPI), 8 have Buy rating, 1 Sell and 19 Hold. Therefore 29% are positive. NXP Semiconductors NV had 60 analyst reports since August 3, 2015 according to SRatingsIntel. Canaccord Genuity maintained it with “Hold” rating and $110.0 target in Friday, August 25 report. The stock has “Hold” rating by Jefferies on Wednesday, October 18. As per Friday, April 8, the company rating was maintained by Pacific Crest. The stock of NXP Semiconductors N.V. (NASDAQ:NXPI) earned “Neutral” rating by Goldman Sachs on Wednesday, February 3. The firm earned “Overweight” rating on Monday, October 12 by Morgan Stanley. Jefferies maintained NXP Semiconductors N.V. (NASDAQ:NXPI) rating on Friday, April 29. Jefferies has “Buy” rating and $130 target. The rating was maintained by Oppenheimer with “Outperform” on Friday, October 30. Stifel Nicolaus maintained it with “Hold” rating and $110.0 target in Friday, September 1 report. FBR Capital maintained NXP Semiconductors N.V. (NASDAQ:NXPI) on Wednesday, November 18 with “Outperform” rating. The stock of NXP Semiconductors N.V. (NASDAQ:NXPI) earned “Hold” rating by Jefferies on Thursday, October 27.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com